2025 H2 -tulosraportti
116 päivää sitten
‧38 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 409 | - | - | ||
| 156 | - | - | ||
| 5 986 | - | - | ||
| 1 148 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·7 t sittenYet another confirmation of how quickly the market for targeted alpha therapy is developing. AdvanCell is now establishing its American headquarters and building a 12,000 m² production facility for Pb-212-based cancer treatments. These are not small investments – they are being made because the company expects significant growth and commercialization. For those of us following Thor Medical, this is interesting. The more companies that invest in Pb-212, the more important a stable and scalable supply of isotopes becomes. The entire ecosystem within Targeted Alpha Therapy seems to be taking a new step forward. 💪🧬
·9 t sitten
·14 t sittenThere might be some who are afraid of missing out before the upcoming holiday. It's not always that easy to stay updated then. We have no idea when there will be a message that the factory is ready for production. The only thing that is certain is that it's getting closer 😉
Save the money now, and buy cheap in August. No point in hyping up something that isn't anything. Happy holidays everyone 🏝️- ·3 päivää sittenThe Lead-212 field continues to mature – yet another positive signal for Thor Medical. AdvanCell has just recruited two highly experienced top executives. One comes from Eli Lilly's focus on radioligand therapy, the other from the role as research director at a leading biotech company. What's interesting is not just the appointments themselves, but where the company is positioned. AdvanCell develops cancer treatment based on Lead-212, and their main candidate is already in Phase I/II. At the same time, they state that they are now preparing for Phase III and commercial scaling. For those of us following Thor Medical, this is interesting because the company is building production capacity for the raw material needed to produce Pb-212. The more companies that succeed with Lead-212 therapies, the greater the need for a secure and stable supply chain. This is, of course, not a guarantee of anything, but it shows that: More companies are investing heavily in Lead-212. The industry is moving from research to industrialization. Experienced leaders from Big Pharma see commercial potential in the technology. For me, this is yet another confirmation that Thor Medical operates in a rapidly developing market. The big values only come when treatments succeed clinically, but all these small pieces point in the same direction. That is precisely why I am long-term in Thor Medical.Just a small clarification to your post, Supertrikker, as it appears a bit unclear: Thor Medical already has a contract with AdvanCell for the delivery of Th‑228, which is the raw material AdvanCell uses in its generators to produce Pb‑212. Thor thus delivers the element, while AdvanCell produces the Pb‑212 itself further down the value chain. This means that the development you describe at AdvanCell – new leaders, preparations for phase III and commercial scaling – is not just a generally positive signal for the Lead‑212 field, but also directly relevant for Thor, since AdvanCell is an actual customer. They also recently visited Thor's new factory precisely to look at the production capacity. So the picture is actually even clearer: When AdvanCell gears up for larger clinical and commercial volumes, the need for Th‑228 increases – and thus for deliveries from Thor Medical.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
116 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittenYet another confirmation of how quickly the market for targeted alpha therapy is developing. AdvanCell is now establishing its American headquarters and building a 12,000 m² production facility for Pb-212-based cancer treatments. These are not small investments – they are being made because the company expects significant growth and commercialization. For those of us following Thor Medical, this is interesting. The more companies that invest in Pb-212, the more important a stable and scalable supply of isotopes becomes. The entire ecosystem within Targeted Alpha Therapy seems to be taking a new step forward. 💪🧬
- ·9 t sitten
- ·14 t sittenThere might be some who are afraid of missing out before the upcoming holiday. It's not always that easy to stay updated then. We have no idea when there will be a message that the factory is ready for production. The only thing that is certain is that it's getting closer 😉Save the money now, and buy cheap in August. No point in hyping up something that isn't anything. Happy holidays everyone 🏝️
- ·3 päivää sittenThe Lead-212 field continues to mature – yet another positive signal for Thor Medical. AdvanCell has just recruited two highly experienced top executives. One comes from Eli Lilly's focus on radioligand therapy, the other from the role as research director at a leading biotech company. What's interesting is not just the appointments themselves, but where the company is positioned. AdvanCell develops cancer treatment based on Lead-212, and their main candidate is already in Phase I/II. At the same time, they state that they are now preparing for Phase III and commercial scaling. For those of us following Thor Medical, this is interesting because the company is building production capacity for the raw material needed to produce Pb-212. The more companies that succeed with Lead-212 therapies, the greater the need for a secure and stable supply chain. This is, of course, not a guarantee of anything, but it shows that: More companies are investing heavily in Lead-212. The industry is moving from research to industrialization. Experienced leaders from Big Pharma see commercial potential in the technology. For me, this is yet another confirmation that Thor Medical operates in a rapidly developing market. The big values only come when treatments succeed clinically, but all these small pieces point in the same direction. That is precisely why I am long-term in Thor Medical.Just a small clarification to your post, Supertrikker, as it appears a bit unclear: Thor Medical already has a contract with AdvanCell for the delivery of Th‑228, which is the raw material AdvanCell uses in its generators to produce Pb‑212. Thor thus delivers the element, while AdvanCell produces the Pb‑212 itself further down the value chain. This means that the development you describe at AdvanCell – new leaders, preparations for phase III and commercial scaling – is not just a generally positive signal for the Lead‑212 field, but also directly relevant for Thor, since AdvanCell is an actual customer. They also recently visited Thor's new factory precisely to look at the production capacity. So the picture is actually even clearer: When AdvanCell gears up for larger clinical and commercial volumes, the need for Th‑228 increases – and thus for deliveries from Thor Medical.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 409 | - | - | ||
| 156 | - | - | ||
| 5 986 | - | - | ||
| 1 148 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
2025 H2 -tulosraportti
116 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittenYet another confirmation of how quickly the market for targeted alpha therapy is developing. AdvanCell is now establishing its American headquarters and building a 12,000 m² production facility for Pb-212-based cancer treatments. These are not small investments – they are being made because the company expects significant growth and commercialization. For those of us following Thor Medical, this is interesting. The more companies that invest in Pb-212, the more important a stable and scalable supply of isotopes becomes. The entire ecosystem within Targeted Alpha Therapy seems to be taking a new step forward. 💪🧬
- ·9 t sitten
- ·14 t sittenThere might be some who are afraid of missing out before the upcoming holiday. It's not always that easy to stay updated then. We have no idea when there will be a message that the factory is ready for production. The only thing that is certain is that it's getting closer 😉Save the money now, and buy cheap in August. No point in hyping up something that isn't anything. Happy holidays everyone 🏝️
- ·3 päivää sittenThe Lead-212 field continues to mature – yet another positive signal for Thor Medical. AdvanCell has just recruited two highly experienced top executives. One comes from Eli Lilly's focus on radioligand therapy, the other from the role as research director at a leading biotech company. What's interesting is not just the appointments themselves, but where the company is positioned. AdvanCell develops cancer treatment based on Lead-212, and their main candidate is already in Phase I/II. At the same time, they state that they are now preparing for Phase III and commercial scaling. For those of us following Thor Medical, this is interesting because the company is building production capacity for the raw material needed to produce Pb-212. The more companies that succeed with Lead-212 therapies, the greater the need for a secure and stable supply chain. This is, of course, not a guarantee of anything, but it shows that: More companies are investing heavily in Lead-212. The industry is moving from research to industrialization. Experienced leaders from Big Pharma see commercial potential in the technology. For me, this is yet another confirmation that Thor Medical operates in a rapidly developing market. The big values only come when treatments succeed clinically, but all these small pieces point in the same direction. That is precisely why I am long-term in Thor Medical.Just a small clarification to your post, Supertrikker, as it appears a bit unclear: Thor Medical already has a contract with AdvanCell for the delivery of Th‑228, which is the raw material AdvanCell uses in its generators to produce Pb‑212. Thor thus delivers the element, while AdvanCell produces the Pb‑212 itself further down the value chain. This means that the development you describe at AdvanCell – new leaders, preparations for phase III and commercial scaling – is not just a generally positive signal for the Lead‑212 field, but also directly relevant for Thor, since AdvanCell is an actual customer. They also recently visited Thor's new factory precisely to look at the production capacity. So the picture is actually even clearer: When AdvanCell gears up for larger clinical and commercial volumes, the need for Th‑228 increases – and thus for deliveries from Thor Medical.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 409 | - | - | ||
| 156 | - | - | ||
| 5 986 | - | - | ||
| 1 148 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt